NASDAQ:FREQ Frequency Therapeutics (FREQ) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free FREQ Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.28▼$0.3250-Day Range$0.22▼$14.9852-Week Range$0.18▼$16.00Volume309,164 shsAverage Volume822,537 shsMarket Capitalization$10.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Frequency Therapeutics alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Frequency Therapeutics Stock (NASDAQ:FREQ)Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… FREQ Stock News HeadlinesMarch 27, 2024 | msn.comExploring the impact of pancreatic enzyme therapy in pediatric pancreatitis: A leap toward personalized medicineMarch 25, 2024 | marketwatch.comStocks to Watch: Stoke Therapeutics, Westport Fuel Systems, Ampco-PittsburghMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 25, 2024 | marketwatch.comStoke Therapeutics Shares Rise 80%, Co. Reports Data From Dravet Syndrome StudyMarch 25, 2024 | msn.comStoke Therapeutics Stock Rockets On Phase 1/2a Data: Here's WhyMarch 22, 2024 | markets.businessinsider.comBuy Rating for Trevi Therapeutics Anchored on Haduvio’s Clinical Promise and Market PotentialMarch 22, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For MesdopetamMarch 20, 2024 | finance.yahoo.comTrevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdatesMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 18, 2024 | markets.businessinsider.comBestqool Unveils Comprehensive Guide to Optimize Red Light Therapy Dosage for Enhanced Health BenefitsMarch 17, 2024 | finanznachrichten.deHeron Therapeutics, Inc.: Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate UpdatesMarch 17, 2024 | msn.comGoing for UV light therapy for acne, eczema, vitiligo? Know which technique works for youMarch 14, 2024 | forbes.comThe Apollo Wearable Review: Get Touch Therapy On Your WristMarch 14, 2024 | businesswire.comCognito Therapeutics Announces Oral Presentation at 2024 American Academy of Neurology (AAN) Annual MeetingMarch 11, 2024 | markets.businessinsider.comBuy Rating on Astria Therapeutics: Anticipating Market Growth with STAR-0215’s Advancements in HAE TreatmentMarch 11, 2024 | msn.comBrittany Mahomes urges moms to "take care of your pelvic floor." Here's why experts agree.March 11, 2024 | tmcnet.comCognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer's DiseaseMarch 7, 2024 | msn.comIV drip therapy: A celeb-approved method to boost health and wellness quicklyMarch 7, 2024 | msn.comNoninvasive Treatment May Protect Patients from Memory Impairment and Cognitive Effects of ChemotherapyMarch 7, 2024 | msn.comLight and sound therapy for Alzheimer’s may also prevent 'chemo brain'March 6, 2024 | msn.comHeat Therapy Can Ease Postworkout Muscle Soreness—Here’s How to Add It to Your RoutineMarch 6, 2024 | msn.comA noninvasive treatment may protect patients from memory impairment and cognitive effects of chemotherapyMarch 6, 2024 | finance.yahoo.comCognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in NeurologyMarch 5, 2024 | msn.comHealth calendar for March 5, 2024March 5, 2024 | msn.comUnderstanding types and therapies for rare blood disordersMarch 5, 2024 | finance.yahoo.comINmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™March 4, 2024 | axios.comExclusive: Soaak raising $28M Series A for sound frequency therapySee More Headlines Receive FREQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FREQ CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.67% Return on Assets-61.40% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$14.07 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book0.15Miscellaneous Outstanding Shares36,520,000Free Float30,385,000Market Cap$10.94 million OptionableNot Optionable Beta0.84 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. David L. Lucchino (Age 53)Co-Founder, President, CEO & Director Comp: $1.02MMr. Richard J. Mitrano (Age 52)Vice President of Finance & Operations Mr. James P. AbelyAssociate General Counsel & SecretaryDr. John L. LaMattina Ph.D. (Age 73)Senior Advisor & Member of PCA Regenerative Medicine Advisory Board Key CompetitorsImunonNASDAQ:IMNNNightHawk BiosciencesNYSE:NHWKMonopar TherapeuticsNASDAQ:MNPRAkari TherapeuticsNASDAQ:AKTXGuardion Health SciencesNASDAQ:GHSIView All CompetitorsInsidersDavid L LucchinoSold 2,865 sharesTotal: $1,719.00 ($0.60/share)Richard J MitranoSold 227 sharesTotal: $143.01 ($0.63/share)David L LucchinoSold 2,895 sharesTotal: $1,881.75 ($0.65/share)Richard J MitranoSold 234 sharesTotal: $156.78 ($0.67/share)David L LucchinoSold 2,881 sharesTotal: $1,815.03 ($0.63/share)View All Insider Transactions FREQ Stock Analysis - Frequently Asked Questions Should I buy or sell Frequency Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares. View FREQ analyst ratings or view top-rated stocks. How were Frequency Therapeutics' earnings last quarter? Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.16. What other stocks do shareholders of Frequency Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX). When did Frequency Therapeutics IPO? Frequency Therapeutics (FREQ) raised $102 million in an initial public offering on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Frequency Therapeutics' major shareholders? Frequency Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carl Lebel, Christopher R Loose, David L Lucchino, Peter P Pfreundschuh, Quentin Mccubbin and Richard J Mitrano. View institutional ownership trends. This page (NASDAQ:FREQ) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Frequency Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.